Manulife (Manufacturers Life Insurance)
BCRX icon

Manulife (Manufacturers Life Insurance)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$971K Buy
102,042
+4,408
+5% +$34.2K ﹤0.01% 1850
2025
Q4 		$762K Sell
97,634
-8,646
-8% -$62.5K ﹤0.01% 1993
2025
Q3 		$807K Sell
106,280
-5,020
-5% -$41.8K ﹤0.01% 1975
2025
Q2 		$997K Buy
111,300
+5,531
+5% +$51.5K ﹤0.01% 1823
2025
Q1 		$793K Buy
105,769
+2,238
+2% +$18.1K ﹤0.01% 1915
2024
Q4 		$779K Sell
103,531
-195,621
-65% -$1.49M ﹤0.01% 2015
2024
Q3 		$2.27M Buy
299,152
+86,571
+41% +$658K ﹤0.01% 1506
2024
Q2 		$1.31M Buy
212,581
+113,152
+114% +$624K ﹤0.01% 1697
2024
Q1 		$505K Buy
99,429
+1,235
+1% +$6.95K ﹤0.01% 2209
2023
Q4 		$588K Buy
98,194
+191
+0.2% +$1.11K ﹤0.01% 2106
2023
Q3 		$694K Buy
98,003
+21,077
+27% +$151K ﹤0.01% 1964
2023
Q2 		$542K Buy
76,926
+2,497
+3% +$20K ﹤0.01% 1985
2023
Q1 		$621K Buy
74,429
+346
+0.5% +$3.33K ﹤0.01% 1874
2022
Q4 		$850K Buy
74,083
+631
+0.9% +$7.87K ﹤0.01% 1693
2022
Q3 		$925K Sell
73,452
-1,285
-2% -$16.5K ﹤0.01% 1642
2022
Q2 		$791K Buy
74,737
+962
+1% +$9.92K ﹤0.01% 1757
2022
Q1 		$1.2M Sell
73,775
-16,950
-19% -$272K ﹤0.01% 1673
2021
Q4 		$1.26K Buy
90,725
+138
+0.2% +$1.83K ﹤0.01% 1692
2021
Q3 		$1.3M Sell
90,587
-8,903
-9% -$140K ﹤0.01% 1673
2021
Q2 		$1.57M Buy
99,490
+426
+0.4% +$5.79K ﹤0.01% 1719
2021
Q1 		$1.01M Sell
99,064
-7,088
-7% -$73.1K ﹤0.01% 1872
2020
Q4 		$791K Buy
106,152
+6,400
+6% +$33K ﹤0.01% 1953
2020
Q3 		$343K Buy
99,752
+7,333
+8% +$31.4K ﹤0.01% 2202
2020
Q2 		$460K Sell
92,419
-5,731
-6% -$22.9K ﹤0.01% 2008
2020
Q1 		$196K Buy
98,150
+27,330
+39% +$75.2K ﹤0.01% 2334
2019
Q4 		$244K Sell
70,820
-1,453
-2% -$3.65K ﹤0.01% 2461
2019
Q3 		$229K Hold
72,273
– – ﹤0.01% 2489
2019
Q2 		$274K Buy
72,273
+473
+0.7% +$2.85K ﹤0.01% 2414
2019
Q1 		$585K Buy
71,800
+4,151
+6% +$35.5K ﹤0.01% 2000
2018
Q4 		$546K Sell
67,649
-5,540
-8% -$43.1K ﹤0.01% 1914
2018
Q3 		$558K Sell
73,189
-3,360
-4% -$22.6K ﹤0.01% 2199
2018
Q2 		$438K Buy
76,549
+1,044
+1% +$5.75K ﹤0.01% 2495
2018
Q1 		$360K Sell
75,505
-1,236
-2% -$6.35K ﹤0.01% 2574
2017
Q4 		$377K Buy
76,741
+13,760
+22% +$66.7K ﹤0.01% 2511
2017
Q3 		$330K Sell
62,981
-135
-0.2% -$691 ﹤0.01% 2578
2017
Q2 		$351K Buy
63,116
+3,774
+6% +$23K ﹤0.01% 2558
2017
Q1 		$498K Buy
59,342
+7,275
+14% +$50.6K ﹤0.01% 2194
2016
Q4 		$329K Sell
52,067
-1,916
-4% -$9.97K ﹤0.01% 2408
2016
Q3 		$238K Sell
53,983
-1,246
-2% -$4.98K ﹤0.01% 2639
2016
Q2 		$157K Buy
55,229
+6,507
+13% +$20.2K ﹤0.01% 2904
2016
Q1 		$133K Buy
48,722
+626
+1% +$2.77K ﹤0.01% 2887
2015
Q4 		$496 Buy
48,096
+498
+1% +$4.95K ﹤0.01% 2031
2015
Q3 		$543 Sell
47,598
-186,733
-80% -$2.49M ﹤0.01% 1945
2015
Q2 		$3.5K Buy
234,331
+187,808
+404% +$2.14M ﹤0.01% 1229
2015
Q1 		$420 Buy
46,523
+1,581
+4% +$16.4K ﹤0.01% 2196
2014
Q4 		$546 Sell
44,942
-1,031
-2% -$11.4K ﹤0.01% 1924
2014
Q3 		$449 Buy
45,973
+1,371
+3% +$16.8K ﹤0.01% 2056
2014
Q2 		$568K Buy
44,602
+42,866
+2,469% +$417K ﹤0.01% 1958
2014
Q1 		$18 Buy
1,736
+115
+7% +$1.23K ﹤0.01% 3307
2013
Q4 		$12 Buy
1,621
+21
+1% +$133 ﹤0.01% 3328
2013
Q3 		$12 Hold
1,600
– – ﹤0.01% 3234
2013
Q2 		$2K Buy
+1,600
New +$2.76K ﹤0.01% 3397

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s BCRX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its BioCryst Pharmaceuticals (BCRX) stake by 4.5% in Q1 2026, buying an estimated $34.2K and bringing the position to 102,042 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Manulife (Manufacturers Life Insurance) first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.27M in Q3 2024. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 102,042 shares of BioCryst Pharmaceuticals worth $971K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 4,408 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $34.2K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1850 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Manulife (Manufacturers Life Insurance)'s BioCryst Pharmaceuticals position peaked at $2.27M in Q3 2024.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.